Chai Discovery, an artificial intelligence drug-discovery company backed by Sam Altman’s OpenAI, has secured $130 million ...

AI in drug discovery is evolving fast. Join the experts behind today’s real progress as they share what works, what doesn’t ...

Chai Discovery, an artificial intelligence drug-discovery company backed by OpenAI, has raised $130 million to build a ...

Discover how Optibrium is transforming early-stage drug discovery through AI-powered software, generative chemistry, and 3D modelling. In this interview, Matt Segall, CEO at Optibrium, shares insights ...

Computational drug discovery and design embodies the integration of advanced computational methods, machine learning, and cheminformatics to streamline the identification and optimisation of ...

Artificial intelligence has already made its mark in commercial industries, and there's a good argument to be made that AI is most impactful in the drug discovery marketplace: Drug discovery companies ...

Despite significant progress in medicinal chemistry and life sciences research, drug discovery and development remain slow and expensive, taking on average approximately 15 years and US$2 billion to ...

Prominent companies operating in the global drug discovery services market include: • Charles River Laboratories (US) • ...

Even though AI-designed drugs aren’t yet a household term for FDA-approved, commercially available therapies, they are a reality in clinical development pipelines. In spring 2024, CBER reported more ...

Clinical trials for drug development are notoriously slow and expensive, and only a small fraction of drug candidates end up being approved by the regulatory authorities. The extensive bottlenecks in ...

Discover what the next wave of AI-assisted drug discovery looks like and how it can help biotech - the AI and physics combo.